Infant Phototherapy Device Market Poised to Reach $140.92 Million by 2033

Introduction

According to Renub Research Latest Report infant phototherapy device market is witnessing steady growth as neonatal jaundice remains a prevalent concern worldwide. Valued at $99.95 million in 2024, the market is projected to reach $140.92 million by 2033, growing at a CAGR of 3.89% from 2025 to 2033. Increasing awareness of neonatal healthcare, technological advancements in phototherapy devices, and rising government and private investments in neonatal care are key factors propelling market growth.

Neonatal jaundice, a common condition among newborns caused by excessive bilirubin accumulation, can lead to severe complications such as brain damage if untreated. Phototherapy remains the standard treatment, exposing infants to specific wavelengths of light—typically blue or green—that convert bilirubin into a water-soluble form that can be eliminated from the body. The advent of LED-based systems and portable phototherapy devices has enhanced both efficiency and accessibility, ensuring timely intervention for newborns in need.

👉 Want to explore detailed market trends, segment insights, and forecasts? 🔗 Request Sample Report

Market Growth Drivers

Rising Prevalence of Neonatal Jaundice

Neonatal jaundice affects a significant percentage of newborns worldwide, particularly in regions with high birth rates or underdeveloped healthcare infrastructure. Prompt treatment is essential to prevent complications, and phototherapy devices have become the preferred intervention. Increasing awareness among healthcare providers and parents has spurred the adoption of phototherapy systems in both hospitals and clinics.

Population dynamics also play a role. For example, China’s relaxation of its one-child policy, allowing couples to have up to three children, has contributed to a higher number of births, increasing the demand for neonatal care devices. In 2023, China recorded 9.02 million births, translating to a birth rate of 6.39 per 1,000 people, highlighting the need for accessible neonatal interventions like phototherapy.

Technological Advancements

Recent innovations, especially in LED phototherapy systems, have significantly improved treatment outcomes. LED devices are energy-efficient, longer-lasting, and can target specific light wavelengths with precision, ensuring effective bilirubin reduction. Portable and compact designs enable healthcare workers to provide treatment in remote or low-resource settings, expanding access to life-saving therapies.

Notable developments include NeoLight’s Skylife Neonatal Phototherapy System, which recently received a group purchasing agreement from Premier, Inc. This agreement enables healthcare providers to acquire the system at more affordable rates, improving accessibility while maintaining high standards of care.

Increased Investment in Neonatal Care

Governments and private institutions worldwide are investing heavily in neonatal healthcare to reduce infant mortality rates. Enhanced infrastructure, equipment procurement, and specialized training for healthcare personnel contribute to the rising adoption of phototherapy devices. Public health initiatives and educational campaigns further promote awareness of neonatal jaundice and the importance of timely treatment.

In February 2024, The Paediatric Neuroimaging Group launched a series of educational animations to help parents understand how premature infants’ developing brains affect respiration and apneas. Such initiatives reflect the broader trend of investing in comprehensive neonatal care, including advanced phototherapy solutions.

Market Challenges

High Cost of Phototherapy Devices

One of the primary barriers in low-income regions is the initial investment required for advanced phototherapy systems, particularly LED-based devices. Maintenance and operational costs further compound the financial burden, limiting adoption in areas with constrained healthcare budgets.

Limited Access in Rural Areas

Rural and remote regions often lack the infrastructure and trained personnel required to administer phototherapy effectively. Supply chain challenges and logistical difficulties further restrict access. Efforts to expand healthcare infrastructure and make devices more affordable and portable are critical to bridging this gap.

Market Segments

Light Source

Fluorescent Lamps: Traditional phototherapy devices emit light in the blue spectrum to break down bilirubin. While energy-intensive and short-lived, they remain widely used due to lower costs, especially in price-sensitive markets.

Light Emitting Diodes (LEDs): Modern LED systems offer energy efficiency, longer lifespan, and targeted wavelength treatment. Their growing popularity is gradually replacing older technologies.

Quartz Halogen Lamps: Known for high brightness and short treatment times, these lamps carry a risk of thermal injury and are increasingly replaced by safer LED devices.

Gas Discharge Tubes: Less common, these tubes are occasionally used for specialized applications in neonatal care.

👉 For deeper analysis, detailed segment data, and company insights: 🔗 Request Customization Report

Configuration

Mobile Devices: Portable phototherapy systems are gaining traction, enabling home-based treatment and access in remote or underserved areas. They are particularly useful for rural regions where hospital access is limited.

Fixed Devices: Stationary systems remain essential in hospitals and neonatal clinics, providing consistent treatment and supporting high patient volumes.

End Users

Hospitals: Major hospitals are the primary adopters, offering advanced phototherapy units and specialized neonatal care.

Neonatal Clinics: These clinics provide targeted care for newborns with jaundice and are increasingly equipped with modern phototherapy devices, particularly in urban areas.

Regional Insights

United States

The U.S. leads the global infant phototherapy market due to a well-established healthcare system, high awareness of neonatal jaundice, and significant investment in medical technology. Home-based treatment adoption and ongoing research initiatives, such as NeoLight’s Skylife system, further strengthen the market.

France

France benefits from a mature healthcare infrastructure, public awareness programs, and strong government support for maternal and neonatal health. Investments in advanced phototherapy technologies enhance the quality of neonatal care, positioning the country as a leader in innovative infant care solutions.

India

India’s infant phototherapy market is expanding rapidly due to high birth rates and growing awareness of neonatal jaundice. While urban centers enjoy advanced facilities, rural areas often face limited access. Initiatives such as Amrita Hospital, Faridabad’s M-NICU—which implements a “zero separation from birth” policy—are improving care standards and expanding market penetration.

Saudi Arabia

Healthcare improvements and investment in medical infrastructure are fueling market growth in Saudi Arabia. Government initiatives to enhance neonatal care and awareness of early jaundice intervention contribute to rising adoption of phototherapy devices. Advanced technologies and increased healthcare spending are creating new opportunities in the region.

Key Market Players

The infant phototherapy device market features several established and emerging companies that focus on innovation, product development, and global expansion. Major players include:

Ningbo David Medical Device Co., Ltd.

Koninklijke Philips N.V.

General Electric Company

Inapiration Healthcare Group Plc

Drägerwerk AG & Co. KGaA

Ibis Medical Equipment and Systems Pvt Ltd.

Weyer GmbH

Natus Medical Incorporated

These companies are adopting strategies such as product portfolio expansion, technological innovation, partnerships, and acquisitions to maintain competitive advantage and drive market growth.

Market Outlook

The infant phototherapy device market is poised for steady growth, with continued advancements in LED technology and portable systems leading the charge. Increasing investments in neonatal healthcare infrastructure, particularly in developing regions, will drive device adoption, while public awareness campaigns help educate caregivers about neonatal jaundice and the importance of early intervention.

Challenges such as high device costs and limited access in rural areas remain, but innovative financing models, mobile solutions, and government-backed initiatives are expected to address these gaps. As neonatal care continues to improve globally, phototherapy devices will remain a critical tool in reducing jaundice-related complications and improving infant health outcomes.

Conclusion

With the global market expected to grow from $99.95 million in 2024 to $140.92 million by 2033, infant phototherapy devices are increasingly recognized as essential tools in neonatal care. Technological innovation, growing awareness, and targeted healthcare investment are shaping a market that is not only expanding in size but also improving the quality of care for newborns worldwide. From urban hospitals to rural clinics, phototherapy systems are poised to make a lasting impact on infant health, offering safe, effective, and accessible solutions for neonatal jaundice.

Note: If you need details, data, or insights not covered in this report, we are glad to assist. Through our customization service, we will collect and deliver the information you require, tailored to your specific needs. Share your requirements with us, and we will update the report to align with your expectations.